HC Wainwright Predicts BioNTech FY2024 Earnings

BioNTech SE (NASDAQ:BNTX) – HC Wainwright issued their FY2024 earnings estimates for BioNTech in a research note issued to investors on Monday, March 10th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($5.24) per share for the year. HC Wainwright has a “Buy” rating and a $150.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at ($3.42) EPS, Q2 2025 earnings at ($3.50) EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($6.43) EPS.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.90 earnings per share.

BNTX has been the subject of several other research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target for the company. Truist Financial assumed coverage on shares of BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 price target for the company. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Finally, Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective for the company. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $143.65.

BioNTech Stock Performance

Shares of BNTX stock opened at $98.39 on Wednesday. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a 50 day moving average price of $116.45 and a 200 day moving average price of $113.13. The firm has a market capitalization of $23.59 billion, a price-to-earnings ratio of -46.85 and a beta of 0.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Daiwa Securities Group Inc. boosted its stake in shares of BioNTech by 7.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock valued at $221,000 after purchasing an additional 128 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after purchasing an additional 150 shares during the period. Probity Advisors Inc. boosted its stake in BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after acquiring an additional 154 shares during the last quarter. Midwest Professional Planners LTD. boosted its stake in BioNTech by 5.8% during the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock valued at $462,000 after acquiring an additional 222 shares during the last quarter. Finally, Perigon Wealth Management LLC boosted its stake in BioNTech by 3.9% during the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company’s stock valued at $666,000 after acquiring an additional 224 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.